Odyssey Therapeutics, Inc.
ODTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.17B
Close$
$-1.07
104% downside
Current Fair Value
104% downsideOvervalued by 104% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.17 Billion |
|---|---|
| Enterprise Value | $1.11 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.39 |
| Beta | 1.43 |
| Outstanding Shares | 30,277,051 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -9.55 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 2.05 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-1.61
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-1.08
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 115.32%▲ 115.32% |
|---|---|
| Total Invested | $653.30M |
| Investors Holding | 59▲ 59.00% |
ESG Score
No data
About Odyssey Therapeutics, Inc.
100 employees
CEO: Gary D. Glick Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an ...